The GLP-1 Podcast Show

Wisenetix

A whole new era of communication in GLP-1 is here!

Now you’ve got the sharpest minds in GLP-1 research right in your pocket. What’s best?

You can listen to them while driving to the hospital, walking between labs, traveling, or just running errands. It’s never been this good or this simple.

Welcome to The GLP-1 Podcast Show, a monthly podcast where you’ll hear cutting-edge perspectives and what’s working in the world of GLP-1. Our aspiration is to be the first place you are going to go to find out what's happening, the latest breakthroughs, clinical updates, and innovations in GLP-1 care and research.

Play

Open in

18 episodes
monthly
Avg 30 min
English

Episodes 18

Newest Oldest Longest

All18 Unplayed18 In progress0 Played0

S1 · E17
November 2 · 43 min
Dr. Ian Justl Ellis: Personalizing GLP-1 Dosing | Ep. 17
In this episode of The GLP-1 Podcast Show, I speak with Dr. Ian Justl Ellis, a board-certified physician and founder of Voafit, about personalized GLP-1 treatment. Drawing on his experience as both a patient and physician, he explains how medication levels change as weekly doses accumulate, why individual responses can vary, and how gradual adjustments guided by appetite, side effects, nutrition, and objective progress support more personalized care. We also discuss patient monitoring, dose delivery challenges, and the clinical research needed to evaluate this approach at scale. Listen now on all major platforms. "The goal is a felt experience that is positive, that is resulting in objective changes." Meet the guest: Dr. Ian Justl Ellis is a board-certified physician and founder and CEO of Voafit. His work focuses on personalized GLP-1 care, precision dosing, and technology that supports individualized medication management. With a background in emergency medicine, fitness, and medical education, Dr. Ellis brings a multidisciplinary perspective to obesity care. Listen to Dr. Ian Justl Ellis on The GLP-1 Podcast Show, available on all major platforms. Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode. Liked this one? Don’t stop now. Here’s what we think you’ll love! What you will learn: (00:00) Highlight (01:47) Introduction (02:52) Personal experience with obesity (08:43) Starting semaglutide (18:40) Precision dosing (25:56) A personalized dosing model (38:37) Dose delivery challenges (43:22) Closing thoughts The GLP-1 Podcast Show is trusted and supported by innovative companies like: - WiseVAs - ZentrixOS - Zentrix Insights 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show YouTube: The GLP-1 Podcast Show Facebook: The GLP-1 Podcast Show TikTok: The GLP-1 Podcast Show
S1 · E16
October 19 · 27 min
Dr. Anders Fink-Jensen: GLP-1 Therapy for Alcohol Use Disorder | Ep. 16
In this episode of The GLP-1 Podcast Show, I speak with Dr. Anders Fink-Jensen, Professor of Psychiatry at the University of Copenhagen and a consultant psychiatrist, about the emerging role of GLP-1 receptor agonists in addiction treatment. We examine the clinical observations that initiated this research, findings from a randomized trial of semaglutide for alcohol use disorder, possible effects on craving, dosing considerations, and the evidence still needed before broader clinical use. Listen now on all major platforms. "Semaglutide reduced both total alcohol consumption and the number of heavy drinking days." Meet the guest: Dr. Anders Fink-Jensen is a professor at the University of Copenhagen and a consultant psychiatrist. His research focuses on psychopharmacology, addiction, severe mental illness, and the clinical evaluation of GLP-1 receptor agonists in people with alcohol use disorder. Listen to Dr. Anders Fink-Jensen on The GLP-1 Podcast Show, available on all major platforms. Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode. Liked this one? Don’t stop now. Here’s what we think you’ll love! What you will learn: (00:00) Highlight (02:06) Introduction (03:03) Origins of addiction research (07:24) Semaglutide trial design (12:06) Alcohol use outcomes (18:10) Patient selection (23:33) Future clinical research (27:06) Closing thoughts The GLP-1 Podcast Show is trusted and supported by innovative companies like: - ZentrixOS - Zentrix Insights - Elevate - WiseVAs 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show YouTube: The GLP-1 Podcast Show Facebook: The GLP-1 Podcast Show TikTok: The GLP-1 Podcast Show
S1 · E15
October 5 · 31 min
Dr. Michelle Gordon: GLP-1 Care for Women in Midlife | Ep. 15
In this episode of The GLP-1 Podcast Show, I speak with Dr. Michelle Gordon, a physician board-certified in obesity medicine and CEO of Thrive Span Medical, about obesity care for women in midlife. We discuss how GLP-1 therapy fits into long-term disease management, why slower weight reduction, adequate protein, resistance training, hydration, and fiber matter, and how hormonal changes may affect weight, cognition, and metabolic health. Dr. Gordon also explains when bariatric surgery remains appropriate and why obesity should be treated as a complex chronic disease. Listen now on all major platforms. "You need the amount of protein to also fuel your muscles, but it has to be coupled with resistance training." Meet the guest: Dr. Michelle Gordon is a physician board-certified in obesity medicine, lifestyle medicine, and general surgery. She is CEO of Thrive Span Medical, a physician-led telehealth clinic focused on midlife weight gain, menopause, and chronic disease. Her clinical work combines obesity medicine, hormone replacement when indicated, evidence-based lifestyle interventions, and personalized long-term care. Listen to Dr. Michelle Gordon on The GLP-1 Podcast Show, available on all major platforms. Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode. Liked this one? Don’t stop now. Here’s what we think you’ll love! What you will learn: (00:00) Highlight (02:42) Introduction (06:08) Gaps in women’s health research (11:20) Muscle preservation during weight loss (15:40) Estrogen and cognitive changes (19:39) Midlife metabolism (22:47) Long-term therapy (31:04) Closing thoughts The GLP-1 Podcast Show is trusted and supported by innovative companies like: - Elevate - WiseVAs - ZentrixOS - Zentrix Insights 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show YouTube: The GLP-1 Podcast Show Facebook: The GLP-1 Podcast Show TikTok: The GLP-1 Podcast Show
S1 · E14
September 21 · 27 min
Dr. Jon Campbell: Understanding GIP and Glucagon | Ep. 14
In this episode of The GLP-1 Podcast Show, I speak with Dr. Jon Campbell, Associate Professor of Medicine at Duke University, about the changing science of GIP and glucagon. We examine GIP physiology, glucagon signaling, weight-independent metabolic effects, multi-receptor agonism, and variability in treatment response. Discover how emerging pharmacology could shape more precise obesity treatment. Listen now on all major platforms. "GI think it’s going to take a little while, but people are going to come around to this idea that glucagon, particularly when combined with an incretin like GIP or GLP-1, is a really powerful way to improve metabolic disease." Meet the guest: Dr. Jon Campbell is an Associate Professor of Medicine at Duke University. His research examines incretin hormones, pancreatic islet biology, and the cellular mechanisms that regulate glucose metabolism. His work has helped advance understanding of GIP, GLP-1, glucagon, and the signaling pathways that may shape future metabolic therapies. Listen to Dr. Jon Campbell on The GLP-1 Podcast Show, available on all major platforms. Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode. What you will learn: (00:00) Highlight (02:11) Introduction (03:18) GIP biology (07:13) Hormone contributions (12:54) Optimized agonists (16:42) Glucagon actions (20:30) Multi-hormone therapies (26:55) Closing thoughts The GLP-1 Podcast Show is trusted and supported by innovative companies like: - Zentrix Insights - ZentrixOS - WiseVAs - Elevate 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show YouTube: The GLP-1 Podcast Show Facebook: The GLP-1 Podcast Show TikTok: The GLP-1 Podcast Show
S1 · E13
September 7 · 35 min
Dr. Ashley Koff: Weight Health in the GLP-1 Era | Ep. 13
In this episode of The GLP-1 Podcast Show, I speak with Dr. Ashley Koff, registered dietitian, founder of The Better Nutrition Program, and bestselling author of Your Best Shot, about weight health in the GLP-1 era. She explains why body composition matters more than total weight, how digestion and hydration shape nutrition outcomes, why protein advice must be personalized, and how clinicians can support more sustainable metabolic health. Listen now on all major platforms. "Weight composition, including the type, amount, and location of bone, muscle, fat, and water, provides a more meaningful signal about health than total weight alone." Meet the guest: Dr. Ashley Koff is a registered dietitian, founder of The Better Nutrition Program, and bestselling author of Your Best Shot: The Personalized System for Optimal Weight Health. She also serves as Nutrition Course Director for the Integrative and Functional Medicine Fellowship at the Susan Samueli Integrative Health Institute. Her work focuses on personalized nutrition, weight health optimization, metabolic health, practitioner education, and helping patients make better, sustainable choices. Listen to Dr. Ashley Koff on The GLP-1 Podcast Show, available on all major platforms. Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode. What you will learn: (00:00) Highlight (02:07) Introduction (05:06) Weight health (07:47) Success markers (10:07) Tracking trends (15:31) Functional status (21:57) Nutrition priorities (31:43) Future care The GLP-1 Podcast Show is trusted and supported by innovative companies like: - WiseVAs - Elevate - Zentrix Insights - ZentrixOS 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show YouTube: The GLP-1 Podcast Show Facebook: The GLP-1 Podcast Show TikTok: The GLP-1 Podcast Show
S1 · E12
August 24 · 33 min
Dr. Timothy Garvey: Adiposity-Based Chronic Disease Explained | Ep. 12
In this episode of The GLP-1 Podcast Show, I speak with Dr. Timothy Garvey, Endowed Professor of Medicine at the University of Alabama at Birmingham, about complication-centric care for Adiposity-Based Chronic Disease. We examine current obesity guidelines, medication selection according to complications, what the key unmet clinical need is in obesity care, and the role of second-generation GLP-1 medications in type 2 diabetes. Listen now on all major platforms. "Obesity treatment should focus on improving complications, quality of life, and health, not simply reaching a target amount of weight loss." Meet the guest: Dr. Timothy Garvey is Endowed Professor and University Professor of Medicine at the University of Alabama at Birmingham. An endocrinologist specializing in obesity and type 2 diabetes, he has authored more than 380 publications and helped establish Adiposity-Based Chronic Disease as a diagnostic framework while leading major obesity guidelines. Listen to Dr. W. Timothy Garvey on The GLP-1 Podcast Show, available on all major platforms. Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode. What you will learn: (00:00) Highlight (02:14) Introduction (07:17) Clinical guidelines (10:35) Complication care (15:34) Medication selection (20:39) Disease evidence (29:40) Diabetes management (33:22) Closing thoughts The GLP-1 Podcast Show is trusted and supported by innovative companies like: - ZentrixOS - Zentrix Insights - Elevate - WiseVAs 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show YouTube: The GLP-1 Podcast Show Facebook: The GLP-1 Podcast Show TikTok: The GLP-1 Podcast Show
S1 · E11
August 3 · 32 min
Dr. Christopher Kramer: Tirzepatide And Cardiovascular Health | Ep. 11
In this episode of The GLP-1 Podcast Show, I speak with Dr. Christopher Kramer, Chief of the Cardiovascular Division at the University of Virginia Health, about how GLP-1 and GIP therapies are reshaping the treatment of obesity-related heart failure. We explore cardiac remodeling, adipose tissue reduction, cardiovascular outcomes, and the mechanisms behind improved patient health. Listen now on all major platforms! "Treatment with tirzepatide reduced heart failure events by approximately fifty percent while helping patients feel better and perform daily activities more comfortably." Meet the guest: Dr. Christopher Kramer earned his A.B. from Harvard and his M.D. from UCSF before completing cardiology training at the University of Pennsylvania. He is the George A. Beller, MD/Lantheus Medical Imaging Distinguished Professor of Cardiovascular Medicine and Chief of the Cardiovascular Division at the University of Virginia Health. His research focuses on cardiovascular magnetic resonance imaging and heart disease. Listen to Dr. Christopher Kramer on The GLP-1 Podcast Show, available on all major platforms. What you will learn: (00:00) Highlight (01:40) Introduction (09:16) Heart failure outcomes (17:55) Cardiac adipose reduction (23:01) Ventricular remodeling (27:42) Weight loss benefits (30:18) Future triple agonists (31:36) Final Questions The GLP-1 Podcast Show is trusted and supported by innovative companies like: - Elevate - WiseVAs - ZentrixOS - Zentrix Insights 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show YouTube: The GLP-1 Podcast Show Facebook: The GLP-1 Podcast Show TikTok: The GLP-1 Podcast Show
S1 · E10
July 6 · 33 min
Dr. Richard DiMarchi: The Evolution of GLP-1 Science | Ep. 10
In this episode of The GLP-1 Podcast Show, I speak with Dr. Richard DiMarchi, Distinguished Professor at Indiana University and a pioneer in peptide therapeutics, about the scientific journey behind GLP-1 therapies, multiagonist drug development, and future obesity treatments. We explore glucagon, GIP, triple agonists, and emerging innovations shaping metabolic medicine. Listen now on all major platforms! "For decades, glucagon was viewed primarily as a hormone that raises blood glucose. Research later revealed that glucagon could also promote weight reduction and improve liver metabolism when balanced appropriately with GLP-1 activity." Meet the guest: Dr. Richard DiMarchi is a Distinguished Professor at Indiana University and a recognized leader in peptide therapeutics, diabetes research, and obesity medicine. His work contributed to major advances in insulin, glucagon, and multiagonist therapies, while also helping establish several biotechnology companies. Dr. DiMarchi continues to advance innovation in the treatment of metabolic diseases through research and translational science. Listen to Dr. Richard DiMarchi on The GLP-1 Podcast Show, available on all major platforms. What you will learn: (00:00) Highlight (01:19) Introduction (05:31) GLP-1 evolution (09:16) Multiagonist design (15:46) Glucagon controversy (17:42) GIP role (24:32) Future treatments (30:13) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show YouTube: The GLP-1 Podcast Show Facebook: The GLP-1 Podcast Show TikTok: The GLP-1 Podcast Show
S1 · E9
June 1 · 29 min
Dr. Sandra Christensen: Preserving Muscle During GLP-1 Treatment | Ep. 09
In this episode of The GLP-1 Podcast Show, I speak with Dr. Sandra Christensen, obesity medicine specialist and founder of Integrative Medical Weight Management. We examine how GLP-1 therapies impact body composition beyond total weight loss. Dr. Christensen explores fat-free mass reduction, muscle and bone considerations, and clinical risks. She also addresses nutrition strategies, resistance training, and the importance of structured monitoring and personalized care. Listen now on all major platforms! "When evaluating weight reduction outcomes, it is essential to distinguish between fat mass and fat-free mass, because each component has different physiological roles and clinical implications." Meet the guest: Dr. Sandra Christensen is an obesity medicine specialist and founder of Integrative Medical Weight Management in Seattle. She holds advanced certification in obesity medicine and serves as a trustee for the Obesity Medicine Association and president of the Washington Obesity Society. Her work focuses on clinical strategies, patient care, and education in obesity treatment. Learn more from Dr. Sandra Christensen on The GLP-1 Podcast Show, available on all major platforms. What you will learn: (00:00) Highlight (01:07) Introduction (02:34) Body composition (04:09) Fat-free mass (07:46) Protein strategies (12:08) Resistance training (14:51) Monitoring tools (25:47) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show
S1 · E8
May 4 · 33 min
Dr. Jason Itri: GLP-1 Microdosing Strategy | Ep. 08
In this episode of The GLP-1 Podcast Show, I speak with Dr. Jason Itri, Founder of Longevity Health Clinic, about how GLP-1 therapies extend beyond weight loss into cardiometabolic optimization. We examine microdosing strategies, insulin resistance, inflammation pathways, and sustainable habit formation through precision prescribing. Dr. Itri highlights practical clinical applications for long-term metabolic health. Listen now on all major platforms! "Lower dose GLP-1 strategies can improve control over dietary habits by reducing impulsive food decisions and supporting consistent behavioral patterns over extended periods." Meet the guest: Dr. Jason Itri is a physician and the founder of Longevity Health Clinic in Virginia, specializing in cardiometabolic health, hormone optimization, and GLP-1 therapies. His work integrates biomarker testing with root-cause physiology to improve metabolic outcomes and reduce long-term disease risk. His clinical focus aligns with advancing precision approaches in obesity medicine and metabolic care. What you will learn: (00:00) Highlight (01:08) Introduction (05:09) Microdosing strategy (07:27) Habit control (15:11) Risk markers (17:11) Insulin resistance (29:10) Muscle loss (32:20) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show
S1 · E7
April 6 · 29 min
Dr. Catherine Toomer: GLP-1 Dosing Strategy | Ep. 07
In this episode of The GLP-1 Podcast Show, I speak with Dr. Catherine Toomer, founder of Total Weight Care Institute and a family medicine physician specializing in metabolic disease. The discussion examines long-term clinical experience using GLP-1 therapies, including dosing strategies, metabolic regulation, and patient-centered obesity care. She also explores insulin resistance, brain signaling, and emerging therapeutic applications. Listen now on all major platforms! “Appetite regulation is strongly influenced by brain signaling pathways, and correcting metabolic signaling often changes hunger perception and eating behavior without relying on willpower alone.” Meet the guest: Dr. Catherine Toomer is a family medicine physician and founder of Total Weight Care Institute, with more than fifteen years of clinical experience using GLP-1 therapies to address metabolic disease and obesity. Her work focuses on correcting metabolic dysregulation through evidence-based medical strategies and personalized care. What you will learn: (00:00) Highlight (00:31) Introduction (01:52) Metabolic disease drivers (05:33) Personalized dosing strategy (07:17) Managing side effects (19:44) Brain appetite signaling (22:40) Future applications (24:50) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show
S1 · E6
March 2 · 37 min
Dr. Caroline Apovian: GLP-1 Game Changers | Ep. 06
In this episode of The GLP-1 Podcast Show, I speak with Dr. Caroline Apovian, Professor of Medicine at Harvard Medical School and Co Director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital, about the evolution of obesity treatment. We discuss why obesity is a chronic disease, how GLP-1 based therapies have changed clinical outcomes, and how they compare with lifestyle intervention and metabolic surgery. Dr. Apovian also addresses stigma, access barriers, and the risks of cosmetic use. Listen now on all major platforms! "Stigma surrounding obesity has forced clinicians to repeatedly prove that treating obesity also prevents cardiovascular disease and diabetes." Meet the guest: Dr. Caroline Apovian is Professor of Medicine at Harvard Medical School and Co Director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital. A founding leader in obesity medicine, her research focuses on adipose tissue inflammation, cardiovascular risk, metabolic surgery, and pharmacotherapy for obesity. To hear Dr. Allison's actual remarks, view the recorded debate here! What you will learn: (00:00) Highlight (01:23) Introduction (04:41) GLP-1 overview (07:55) Obesity disease model (13:35) Treatment comparisons (19:59) Cardiovascular outcomes (25:44) Cosmetic use debate (33:22) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show
S1 · E5
February 2 · 32 min
Melissa Mitri: Nutrition & GLP-1’s | Ep. 05
In this episode of The GLP-1 Podcast Show, I speak with Melissa Mitri, Registered Dietitian and weight loss expert at Melissa Mitri Nutrition, about real-world nutrition strategies for patients using GLP-1 therapies. She focuses on nutrient density, meal structure, side effect management, muscle preservation, and long-term habit building. Melissa shares clinical insights from nearly two decades of practice working directly with patients. Melissa highlights how nutrition and lifestyle optimize outcomes alongside GLP-1 medications. Listen now on all major platforms! “GLP-1 therapies shift nutrition counseling away from calorie obsession toward nutrient density, because patients eat smaller portions and every bite must support metabolic health.” Meet the guest: Melissa Mitri, MS, RD, is a Registered Dietitian, weight loss expert, and founder of Melissa Mitri Nutrition. She specializes in sustainable weight management, including nutrition support for patients using GLP-1 therapies. With nearly 20 years of clinical experience, her work focuses on nutrient density, habit formation, and evidence based care. Connect with our guest on Social Media: LinkedIn Instagram GLP-1 Cheat Sheet for Clinicians What you will learn: (00:00) Highlight (00:45) Introduction (02:27) Nutrition approach (04:59) Meal timing (07:23) Side effects (12:14) Muscle preservation (17:35) Long-term habits (29:49) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show
S1 · E4
January 5 · 28 min
Dr. Ken Fujioka: Next GLP-1 Era | Ep. 04
In this episode of The GLP-1 Podcast Show, I speak with Dr. Ken Fujioka, Clinical Professor of Medicine and Director of the Nutrition and Metabolic Research Center at Scripps Clinic, about the clinical evolution of GLP-1-based therapies. He covers next-generation dual and triple agonists, dose titration, nausea management, and long-term weight maintenance. Dr. Fujioka also examines oral alternatives, safety concerns, and real-world prescribing considerations. Listen now on all major podcast platforms! "Combining multiple satiety hormones allows greater weight reduction by targeting complementary brain and gastrointestinal pathways involved in appetite regulation." Meet the guest: Dr. Ken Fujioka is a Clinical Professor of Medicine and Director of the Nutrition and Metabolic Research Center at Scripps Clinic, specializing in obesity, diabetes, and metabolic disease management. His work focuses on clinical trials, patient-centered weight treatment, and GLP-1-based therapies. What you will learn: (00:00) Highlight (00:57) Introduction (02:59) New GLP-1 agents (05:12) Dose titration (08:14) Glucagon role (10:29) Clinical precautions (12:53) Oral alternatives (22:42) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show
S1 · E3
Dec 1, 2025 · 29 min
Dr. Jens Juul Holst: GLP-1 in Modern Medicine | Ep. 03
In this episode of The GLP-1 Podcast Show, I speak with Dr. Jens Juul Holst, Professor of Medical Physiology at the University of Copenhagen and Senior Group Leader at the Novo Nordisk Foundation Center for Basic Metabolic Research. We explore the discovery of GLP-1, its evolution into today’s leading therapies for diabetes and obesity, and the molecular and clinical mechanisms that drive their success. Listen now on all major platforms. “The incretin hormones GLP-1 and GIP amplify insulin secretion after meals, ensuring glucose tolerance and maintaining energy balance across multiple tissues.” Meet the guest: Dr. Jens Juul Holst is Professor of Medical Physiology at the University of Copenhagen and Senior Group Leader at the Novo Nordisk Foundation Center for Basic Metabolic Research. His research focuses on metabolic hormones, appetite regulation, and the pathophysiology of obesity and type 2 diabetes. Known for co-discovering GLP-1, his work has shaped modern metabolic therapy. What you will learn: (00:00) Highlight (00:58) Introduction (02:07) GLP-1 mechanism (05:00) Discovery process (07:35) Therapeutic development (11:19) Cardiovascular effects (15:08) Broader metabolic impact (20:27) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show
S1 · E2
Nov 3, 2025 · 27 min
Dr. Michael Nauck: GLP-1 Origins | Ep. 02
In this episode of The GLP-1 Podcast Show, I speak with Dr. Michael Nauck, Head of Clinical Research at the Diabetes Division of St. Josef-Hospital, Ruhr-University Bochum, Germany. We explore the early discoveries behind incretin hormones, the development of GLP-1–based therapies, and their expanding role in diabetes, obesity, and cardiovascular care. Dr. Nauck also discusses the next generation of dual and triple agonists shaping obesity medicine. Listen now on all major platforms. “For the first time, weight loss medications, like GLP-1, achieved meaningful reductions without serious safety concerns.” Meet the guest: Dr. Michael Nauck is Head of Clinical Research at the Diabetes Division, St. Josef-Hospital, Ruhr-University Bochum, Germany. His pioneering work on incretin hormones established the scientific foundation for GLP-1–based therapies in type 2 diabetes. With a research focus on metabolic regulation and cardiovascular outcomes, Dr. Nauck continues to advance innovation in endocrinology and obesity care. What you will learn: (00:00) Highlight (01:09) Introduction (02:18) Incretin effect explained (06:38) Early GLP-1 discoveries (08:39) DPP-4 inhibitors’ role (12:12) Beyond glucose control (16:44) Mechanisms of GLP-1 (22:51) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show
S1 · E1
Sep 29, 2025 · 28 min
Dr. Michael Schwartz: GLP-1 and Brain Pathways | Ep. 01
The GLP-1 Podcast Show is a new podcast created to spotlight the science, perspectives, and leaders shaping the future of obesity treatment and metabolic medicine. In this first episode, we welcome Dr. Michael Schwartz, Robert H. Williams Endowed Chair and Professor of Medicine at the University of Washington, who speaks with Areesha Moiz about how GLP-1 receptor agonists reshape obesity treatment. The discussion covers adaptive responses to weight loss, brain regulation of appetite, mechanisms of long-acting drugs, and the challenges of sustaining results after treatment withdrawal. It also highlights emerging therapeutic strategies to prolong weight loss. Listen now on all major platforms! "GLP-1 receptor agonists are unique because they continuously and maximally activate their target, creating effects that natural peptides could never achieve." Meet the guest: Dr. Michael Schwartz received his MD from Rush Medical College and trained in endocrinology and metabolism at the University of Washington. He is internationally recognized for his research on brain mechanisms controlling body weight, glucose homeostasis, obesity, and diabetes. A recipient of numerous awards, Dr. Schwartz has published nearly 300 papers and directed major research institutes in Seattle. What you will learn: (00:00) Highlight (01:15) Introduction (03:26) GLP-1 drug design (07:51) Appetite regulation (10:23) Adaptive response (14:39) Weight regain (17:55) Maintenance strategies (24:44) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: The GLP-1 Podcast Show Instagram: The GLP-1 Podcast Show LinkedIn: The GLP-1 Podcast Show
Jun 30, 2025 · 50 sec
Welcome to The GLP-1 Podcast Show!
A whole new era of communication in GLP-1 is here! Now you’ve got the sharpest minds in GLP-1 research right in your pocket. What’s best? You can listen to them while driving to the hospital, walking between labs, traveling, or just running errands. Now it’s never been this good or this simple. Welcome to The GLP-1 Podcast Show, a monthly podcast where you’ll hear cutting-edge perspectives and what’s working in the world of GLP-1. Our aspiration is to be the first place you are going to go to find out what's happening, the latest breakthroughs, clinical updates, and innovations in GLP-1 care and research.

Showing 1–18 of 18 episodes